In its most recent SEC filing, Banyan Capital Management Inc. reported acquiring 3,853 shares of Johnson & Johnson during the third quarter, representing an investment of approximately $714,000. This position now accounts for roughly 0.3% of Banyan’s total assets, making it the firm’s 22nd largest holding. The move underscores Banyan’s view of Johnson & Johnson as a stable, dividend-paying cornerstone within a diversified portfolio. Institutional ownership of J&J remains high, with 69.6% of shares held by large funds, suggesting that Banyan’s addition aligns with broader market trends favoring blue-chip healthcare names.

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion on AKEEGA, Johnson & Johnson’s combination therapy of niraparib and abiraterone, for patients with BRCA1/2-mutant metastatic hormone-sensitive prostate cancer. If approved, this indication could add a new revenue stream to the pharma division, with analysts projecting peak annual sales of $1.2 billion. This regulatory endorsement enhances visibility into J&J’s late-stage pipeline and underpins consensus forecasts for mid-single-digit pharmaceutical sales growth over the next five years.

Several brokerage firms have raised their outlooks on Johnson & Johnson. Daiwa Capital Markets maintained its Outperform rating while boosting its target to $237, Morgan Stanley upgraded J&J citing an improved growth trajectory, and Scotiabank increased its target to $265 following robust quarterly results. On the legal front, a U.S. federal judge dismissed a fraud lawsuit challenging J&J’s talc bankruptcy strategy, removing a near-term overhang on the balance sheet. However, commentators caution that broader talc liabilities remain unresolved, keeping potential litigation risk in the background as investors weigh the company’s 58-year dividend streak and 2.3% yield against its debt-to-equity ratio of 0.50.